Piechota Mariusz, Piechota Anna, Misztal Małgorzata, Bernas Szymon, Pietraszek-Grzywaczewska Iwona
Department of Anaesthesiology and Intensive Therapy - Centre for Artificial Extracorporeal Kidney and Liver Support, Dr Wł. Biegański Regional Specialist Hospital, Lodz, Poland.
Department of Insurance, Faculty of Economics and Sociology, University of Lodz, Lodz, Poland.
Arch Med Sci. 2019 Jan;15(1):99-112. doi: 10.5114/aoms.2017.67998. Epub 2017 May 25.
The mortality rate in patients with severe liver dysfunction with no option of transplantation is unacceptably high. The main aim of this study was to evaluate the usefulness of applying extracorporeal liver support (ECLS) techniques in this group of patients.
Data from hospital admissions of 101 patients with severe liver dysfunction who were admitted to the department of Anaesthesiology and intensive therapy between 2006 and 2015 were retrospectively analysed. The study group was divided into two subgroups. Standard Medical therapy (SMT) was a subgroup of patients receiving standard Medical therapy, and SMT + ECLS was a subgroup containing patients receiving standard medical therapy complemented by at least one extracorporeal liver support procedure.
Significantly lower intensive care unit (ICU) mortality and 30-day mortality rates were found in the SMT + ECLS subgroup ( = 0.0138 and = 0.0238 respectively). No difference in 3-month mortality was identified between the two groups. In a multivariate model, independent risk factors for ICU mortality proved to be the SOFA score and prothrombin time. The highest discriminatory power for ICU mortality was demonstrated for the SOFA score, followed by APACHE II, SAPS II, MELD UNOS and GCS scores. For 30-day mortality, however, the best discriminatory power was shown for the SAPS II score, followed by SOFA, APACHE II, MELD UNOS and GCS scores.
Further studies are needed to assess the contribution of non-biological extracorporeal liver support procedures to a decrease in mortality rates in the population of patients with severe liver dysfunction.
对于严重肝功能不全且无移植选择的患者,其死亡率高得令人难以接受。本研究的主要目的是评估在这组患者中应用体外肝脏支持(ECLS)技术的有效性。
回顾性分析了2006年至2015年间麻醉与重症治疗科收治的101例严重肝功能不全患者的住院数据。研究组分为两个亚组。标准药物治疗(SMT)亚组为接受标准药物治疗的患者,SMT + ECLS亚组为接受标准药物治疗并辅以至少一种体外肝脏支持程序的患者。
SMT + ECLS亚组的重症监护病房(ICU)死亡率和30天死亡率显著降低(分别为 = 0.0138和 = 0.0238)。两组之间未发现3个月死亡率有差异。在多变量模型中,ICU死亡率的独立危险因素被证明是序贯器官衰竭评估(SOFA)评分和凝血酶原时间。SOFA评分对ICU死亡率的鉴别能力最强,其次是急性生理与慢性健康状况评分系统II(APACHE II)、简化急性生理学评分系统II(SAPS II)、终末期肝病模型(MELD UNOS)和格拉斯哥昏迷评分(GCS)。然而,对于30天死亡率,SAPS II评分的鉴别能力最佳,其次是SOFA、APACHE II、MELD UNOS和GCS评分。
需要进一步研究来评估非生物体外肝脏支持程序对降低严重肝功能不全患者死亡率的作用。